51,263 Shares in Janux Therapeutics, Inc. $JANX Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 51,263 shares of the company’s stock, valued at approximately $711,000. Hsbc Holdings PLC owned about 0.08% of Janux Therapeutics at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Janux Therapeutics in the fourth quarter worth $34,000. Osaic Holdings Inc. boosted its stake in Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after purchasing an additional 3,037 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Janux Therapeutics during the 4th quarter valued at about $51,000. Tower Research Capital LLC TRC raised its holdings in Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after buying an additional 2,502 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in shares of Janux Therapeutics by 185.1% in the second quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock worth $177,000 after buying an additional 4,982 shares in the last quarter. 75.39% of the stock is owned by institutional investors.

Insider Activity

In other news, VP Maria Dobek sold 2,038 shares of Janux Therapeutics stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $14.17, for a total transaction of $28,878.46. Following the transaction, the vice president directly owned 32,270 shares of the company’s stock, valued at $457,265.90. The trade was a 5.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Janeen Noel Doyle sold 4,059 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the sale, the insider owned 75,941 shares in the company, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on JANX. UBS Group lowered shares of Janux Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $57.00 to $15.00 in a report on Wednesday, April 15th. Wedbush reduced their price objective on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, May 8th. Guggenheim decreased their target price on Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Piper Sandler lowered their target price on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, JonesTrading dropped their price target on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, April 28th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.08.

Janux Therapeutics Stock Up 4.1%

Shares of NASDAQ:JANX opened at $15.58 on Friday. Janux Therapeutics, Inc. has a twelve month low of $12.12 and a twelve month high of $35.34. The stock has a market capitalization of $950.07 million, a PE ratio of -8.47 and a beta of 2.52. The firm’s 50 day moving average price is $14.90 and its 200-day moving average price is $14.37.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.13. The business had revenue of $3.73 million during the quarter, compared to the consensus estimate of $4.36 million. Analysts expect that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.